Net Loss Per Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

Note 20 — Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Years Ended December 31,
	2022			2021
Numerator
Net loss - before noncontrolling interest	$	(103,238	)	$	(56,126	)
Net loss attributable to noncontrolling interest		14,255			5,779
Net loss - as reported, attributable to PAVmed Inc.	$	(88,983	)	$	(50,347	)
Series B Convertible Preferred Stock dividends – earned	$	(281	)	$	(283	)
Net loss attributable to PAVmed Inc. common stockholders	$	(89,264	)	$	(50,630	)
Denominator
Weighted average common shares outstanding, basic and diluted		89,076,078			77,515,767
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(1.00	)	$	(0.65	)
Net loss attributable to PAVmed Inc. common stockholders	$	(1.00	)	$	(0.65	)

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

The Series B Convertible Preferred Stock dividends earned as of each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors.

Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2022 and 2021 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

	December 31,
	2022		2021
Stock options and restricted stock awards		12,543,655		10,386,864
Series Z Warrants		11,937,450		11,937,455
Series W Warrants		—		377,873
Series B Convertible Preferred Stock		1,205,759		1,113,919
Total		25,686,864		23,816,111

The total stock options and restricted stock awards are inclusive of 500,854 stock options as of December 31, 2022 and 2021; and 100,000 restricted stock awards as of December 31, 2022 and 2021, granted outside the PAVmed Inc. 2014 Equity Plan.